Clarity Pharmaceuticals Ltd (1F4.F)
Frankfurt · EUR · Healthcare · Biotechnology
€0.95 (-1.55%) as of
Key statistics
- Market cap
- 354.43M
- EPS (TTM)
- -0.1700
- Dividend yield
- 0.00%
- 52-week range
- 0.9500 – 2.5685
- Beta
- 1.18
- Revenue (TTM)
- 10.53M
- Profit margin
- 0.00%
- Volume
- 342.00
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Sydney, NSW, Australia
- Employees
- 100
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.